Cantor Fitzgerald Has Weak Forecast for VKTX FY2025 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, October 23rd. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings of ($2.87) per share for the year, down from their prior estimate of ($2.72). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Viking Therapeutics’ FY2026 earnings at ($4.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.14). The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.22) earnings per share.

Several other analysts also recently commented on VKTX. JPMorgan Chase & Co. lowered their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $125.00 price objective on shares of Viking Therapeutics in a research note on Monday, September 22nd. Zacks Research downgraded Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Friday. Finally, B. Riley upgraded Viking Therapeutics to a “strong-buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.62.

Viking Therapeutics Trading Up 1.5%

Shares of NASDAQ:VKTX opened at $34.42 on Monday. The stock’s fifty day simple moving average is $28.57 and its two-hundred day simple moving average is $28.83. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.73. The stock has a market cap of $3.89 billion, a PE ratio of -16.24 and a beta of 0.64.

Institutional Investors Weigh In On Viking Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avion Wealth lifted its holdings in Viking Therapeutics by 1,157.0% during the third quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,400 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Viking Therapeutics by 18,630.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 13,673 shares of the biotechnology company’s stock valued at $359,000 after buying an additional 13,600 shares in the last quarter. Ethos Financial Group LLC boosted its holdings in Viking Therapeutics by 4.0% in the 3rd quarter. Ethos Financial Group LLC now owns 10,969 shares of the biotechnology company’s stock worth $288,000 after buying an additional 421 shares during the period. SG Americas Securities LLC grew its stake in Viking Therapeutics by 570.7% in the 3rd quarter. SG Americas Securities LLC now owns 95,804 shares of the biotechnology company’s stock valued at $2,518,000 after buying an additional 81,519 shares in the last quarter. Finally, Global Retirement Partners LLC raised its holdings in Viking Therapeutics by 80.2% during the 3rd quarter. Global Retirement Partners LLC now owns 2,433 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 1,083 shares during the period. 76.03% of the stock is currently owned by institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.